273 related articles for article (PubMed ID: 7752202)
1. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
[TBL] [Abstract][Full Text] [Related]
2. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
Amin KM; Ismail MM; Noaman E; Soliman DH; Ammar YA
Bioorg Med Chem; 2006 Oct; 14(20):6917-23. PubMed ID: 16843668
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1,4-di-N-oxides. 2.
Monge A; Martínez-Crespo FJ; López de Ceráin A; Palop JA; Narro S; Senador V; Marín A; Sainz Y; González M; Hamilton E
J Med Chem; 1995 Oct; 38(22):4488-94. PubMed ID: 7473576
[TBL] [Abstract][Full Text] [Related]
4. Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs.
Gali-Muhtasib HU; Haddadin MJ; Rahhal DN; Younes IH
Oncol Rep; 2001; 8(3):679-84. PubMed ID: 11295102
[TBL] [Abstract][Full Text] [Related]
5. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
Brown JM
Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.
Urquiola C; Vieites M; Torre MH; Cabrera M; Lavaggi ML; Cerecetto H; González M; Cerain AL; Monge A; Smircich P; Garat B; Gambino D
Bioorg Med Chem; 2009 Feb; 17(4):1623-9. PubMed ID: 19162490
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
8. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
9. New quinoxalinecarbonitrile 1,4-di-N-oxide derivatives as hypoxic-cytotoxic agents.
Ortega MA; Morancho MJ; Martínez-Crespo FJ; Sainz Y; Montoya ME; López de Ceráin A; Monge A
Eur J Med Chem; 2000 Jan; 35(1):21-30. PubMed ID: 10733600
[TBL] [Abstract][Full Text] [Related]
10. Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075).
Riley RJ; Hemingway SA; Graham MA; Workman P
Biochem Pharmacol; 1993 Mar; 45(5):1065-77. PubMed ID: 8461036
[TBL] [Abstract][Full Text] [Related]
11. Discovery of derivatives of 6(7)-amino-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: novel, hypoxia-selective HIF-1α inhibitors with strong antiestrogenic potency.
Buravchenko GI; Scherbakov AM; Dezhenkova LG; Bykov EE; Solovieva SE; Korlukov AA; Sorokin DV; Monzote Fidalgo L; Shchekotikhin AE
Bioorg Chem; 2020 Nov; 104():104324. PubMed ID: 33142432
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships for benzotriazine di-N-oxides.
Zeman EM; Baker MA; Lemmon MJ; Pearson CI; Adams JA; Brown JM; Lee WW; Tracy M
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):977-81. PubMed ID: 2703405
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
Walton MI; Workman P
J Pharmacol Exp Ther; 1993 May; 265(2):938-47. PubMed ID: 8496834
[TBL] [Abstract][Full Text] [Related]
14. Heterocyclic mono-N-oxides with potential applications as bioreductive anti-tumour drugs: Part 1. 8-Alkylamino-substituted phenylimidazo [1,2-a] quinoxalines.
Naylor MA; Stephens MA; Nolan J; Sutton B; Tocher JH; Fielden EM; Adams GE; Stratford IJ
Anticancer Drug Des; 1993 Dec; 8(6):439-61. PubMed ID: 8286012
[TBL] [Abstract][Full Text] [Related]
15. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Abe M
Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
[TBL] [Abstract][Full Text] [Related]
16. Selective hypoxia-cytotoxins based on vanadyl complexes with 3-aminoquinoxaline-2-carbonitrile-N1,N4-dioxide derivatives.
Vieites M; Noblía P; Torre MH; Cerecetto H; Laura Lavaggi M; Costa-Filho AJ; Azqueta A; de Cerain AL; Monge A; Parajón-Costa B; González M; Gambino D
J Inorg Biochem; 2006 Aug; 100(8):1358-67. PubMed ID: 16698084
[TBL] [Abstract][Full Text] [Related]
17. Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
Johnson KM; Parsons ZD; Barnes CL; Gates KS
J Org Chem; 2014 Aug; 79(16):7520-31. PubMed ID: 25029663
[TBL] [Abstract][Full Text] [Related]
18. Chemical properties which control selectivity and efficacy of aromatic N-oxide bioreductive drugs.
Wardman P; Priyadarsini KI; Dennis MF; Everett SA; Naylor MA; Patel KB; Stratford IJ; Stratford MR; Tracy M
Br J Cancer Suppl; 1996 Jul; 27():S70-4. PubMed ID: 8763850
[TBL] [Abstract][Full Text] [Related]
19. New quinoxaline 1, 4-di-N-oxides: anticancer and hypoxia-selective therapeutic agents.
Ismail MM; Amin KM; Noaman E; Soliman DH; Ammar YA
Eur J Med Chem; 2010 Jul; 45(7):2733-8. PubMed ID: 20236735
[TBL] [Abstract][Full Text] [Related]
20. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
